Q3 Earnings Forecast for Vera Therapeutics Issued By Wedbush

Key Points

• Wedbush has reduced its Q3 2025 EPS estimates for Vera Therapeutics from ($0.79) to ($1.16), maintaining a "Neutral" rating with a price target of $26.00.
• The company's latest earnings report showed a loss of ($1.20) EPS, missing the consensus estimate by ($0.38).
• Vera Therapeutics has a current consensus rating of "Moderate Buy" from analysts, with an average target price of $65.00.

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Equities researchers at Wedbush cut their Q3 2025 EPS estimates for shares of Vera Therapeutics in a research note issued to investors on Tuesday, August 5th. Wedbush analyst L. Chico now forecasts that the company will earn ($1.16) per share for the quarter, down from their prior forecast of ($0.79). Wedbush currently has a "Neutral" rating and a $26.00 price target on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. Wedbush also issued estimates for Vera Therapeutics' Q4 2025 earnings at ($1.20) EPS, FY2025 earnings at ($4.37) EPS, Q1 2026 earnings at ($1.23) EPS, Q2 2026 earnings at ($1.32) EPS, Q3 2026 earnings at ($1.38) EPS, Q4 2026 earnings at ($1.13) EPS, FY2026 earnings at ($5.03) EPS, FY2027 earnings at ($4.12) EPS, FY2028 earnings at ($2.55) EPS and FY2029 earnings at ($1.49) EPS.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.38). During the same period last year, the company earned ($0.62) earnings per share.

VERA has been the topic of a number of other research reports. Guggenheim reaffirmed a "buy" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Wolfe Research restated a "peer perform" rating on shares of Vera Therapeutics in a research note on Monday. HC Wainwright reiterated a "buy" rating and set a $85.00 price objective (up from $75.00) on shares of Vera Therapeutics in a research report on Monday, June 2nd. Cantor Fitzgerald decreased their price objective on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Finally, Scotiabank reaffirmed an "outperform" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Vera Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $65.00.

Vera Therapeutics Price Performance

Shares of NASDAQ VERA opened at $19.25 on Thursday. The company has a debt-to-equity ratio of 0.10, a current ratio of 27.68 and a quick ratio of 27.68. The firm has a market capitalization of $1.23 billion, a PE ratio of -5.38 and a beta of 1.17. Vera Therapeutics has a 1-year low of $18.53 and a 1-year high of $51.61. The business's fifty day moving average price is $22.96 and its two-hundred day moving average price is $25.33.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Huntington National Bank bought a new position in shares of Vera Therapeutics during the 4th quarter valued at about $26,000. GF Fund Management CO. LTD. acquired a new stake in Vera Therapeutics during the fourth quarter valued at approximately $56,000. Quarry LP boosted its holdings in Vera Therapeutics by 25.0% during the first quarter. Quarry LP now owns 2,500 shares of the company's stock worth $60,000 after buying an additional 500 shares in the last quarter. AlphaQuest LLC boosted its holdings in Vera Therapeutics by 404.7% during the first quarter. AlphaQuest LLC now owns 4,007 shares of the company's stock worth $96,000 after buying an additional 3,213 shares in the last quarter. Finally, Fifth Third Bancorp acquired a new position in Vera Therapeutics in the second quarter worth approximately $102,000. Institutional investors own 99.21% of the company's stock.

Insiders Place Their Bets

In other news, Director Patrick G. Enright purchased 40,607 shares of the stock in a transaction dated Tuesday, June 24th. The shares were bought at an average cost of $22.35 per share, for a total transaction of $907,566.45. Following the transaction, the director owned 3,596,593 shares in the company, valued at $80,383,853.55. This trade represents a 1.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 16.30% of the stock is owned by company insiders.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.